Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms
暂无分享,去创建一个
[1] R. Touyz,et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.
[2] M. Vacca,et al. Integrative miRNA and whole-genome analyses of epicardial adipose tissue in patients with coronary atherosclerosis. , 2016, Cardiovascular research.
[3] Alexander S. Banks,et al. SirT1 Regulates Adipose Tissue Inflammation , 2011, Diabetes.
[4] Benjamin S. Aribisala,et al. Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes , 2015, Diabetes Care.
[5] D. Webb,et al. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. , 1996, Circulation.
[6] Y. Hung,et al. Circulating pro-inflammatory cytokines and adiponectin in young men with type 2 diabetes , 2011, Acta Diabetologica.
[7] R. DeFronzo,et al. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. , 1975, The Journal of clinical investigation.
[8] E. Ferrannini,et al. β-Cell function in type 2 diabetes. , 2014, Metabolism: clinical and experimental.
[9] C. Spadaccio,et al. Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease , 2015, Research in cardiovascular medicine.
[10] E. Ferrannini,et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis , 2016, Diabetes Care.
[11] S. Haffner,et al. Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites. San Antonio Heart Study. , 1990, American journal of epidemiology.
[12] A. Mooradian. Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm , 2016, Drugs.
[13] J. Shaw,et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. , 2011, Diabetes research and clinical practice.
[14] K. Andrews,et al. NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis , 2013, Circulation.
[15] P. Libby,et al. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. , 2007, The American journal of cardiology.
[16] Seppo Lehto,et al. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. , 2005, Diabetes care.
[17] M. Donath. Targeting inflammation in the treatment of type 2 diabetes: time to start , 2014, Nature Reviews Drug Discovery.
[18] Xiaomin Liu,et al. Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus. , 2008, The American journal of cardiology.
[19] M. Barton,et al. Accelerated Vascular Aging as a Paradigm for Hypertensive Vascular Disease: Prevention and Therapy. , 2016, The Canadian journal of cardiology.
[20] John S Yudkin,et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.
[21] I. Alexa,et al. [Oxidative stress in atherosclerosis]. , 2003, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi.
[22] Ann L. Albright,et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. , 2010, JAMA.
[23] S. Haffner,et al. Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study , 2013, Diabetologia.
[24] Jiang He,et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. , 2015, Circulation.
[25] S. Kaneko,et al. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization , 2016, Diabetes.
[26] F. Cosentino,et al. Epigenetics and Immunometabolism in Diabetes and Aging , 2017, Antioxidants & redox signaling.
[27] P. Scherer,et al. Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis , 2013, Journal of Lipid Research.
[28] D. Kass,et al. Mechanisms, pathophysiology, and therapy of arterial stiffness. , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[29] K. Jandeleit-Dahm,et al. Linking RAGE and Nox in diabetic micro- and macrovascular complications. , 2015, Diabetes & metabolism.
[30] Andrea De Gaetano,et al. Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes , 2013, Diabetes Care.
[31] T. Sano,et al. [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.
[32] Tanya M. Teslovich,et al. The Metabochip, a Custom Genotyping Array for Genetic Studies of Metabolic, Cardiovascular, and Anthropometric Traits , 2012, PLoS genetics.
[33] A. Planas,et al. Sphingosine-1-phosphate signalling—a key player in the pathogenesis of Angiotensin II-induced hypertension , 2017, Cardiovascular research.
[34] J. Uribarri,et al. Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both? , 2013, Current Diabetes Reports.
[35] P Ducimetière,et al. Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. , 1993, BMJ.
[36] E. Ferrannini. Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology. , 2017, Cell metabolism.
[37] Myung‐Sook Choi,et al. Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease , 2014, International journal of molecular sciences.
[38] R. Touyz,et al. Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[39] R. Neviere,et al. Kidney, heart and brain: three organs targeted by ageing and glycation. , 2017, Clinical science.
[40] R. Brook,et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.
[41] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[42] M. Volpe,et al. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. , 2017, Cardiovascular research.
[43] D. Kass,et al. Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink Breaker , 2001, Circulation.
[44] R. Touyz,et al. Drug Treatment of Hypertension: Focus on Vascular Health , 2016, Drugs.
[45] Xinghui Sun,et al. Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy. , 2017, Endocrine reviews.
[46] R. de Caterina,et al. Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches. , 2017, Vascular pharmacology.
[47] N. Billestrup,et al. Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus , 2011, Molecular medicine.
[48] M. Woodward,et al. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes , 2017, Cardiovascular Diabetology.
[49] R. Ramasamy,et al. Unlocking the biology of RAGE in diabetic microvascular complications , 2014, Trends in Endocrinology & Metabolism.
[50] Michael Brownlee,et al. The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.
[51] M. Volpe,et al. Vascular Inflammation and Endothelial Dysfunction in Experimental Hypertension , 2011, International journal of hypertension.
[52] O. Pedersen,et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial , 2016, Diabetologia.
[53] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[54] Saum A. Rahimi,et al. Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques. , 2016, Cardiovascular research.
[55] N. Agrawal,et al. Targeting inflammation in diabetes: Newer therapeutic options. , 2014, World journal of diabetes.
[56] S. Quaggin,et al. Therapies on the Horizon for Diabetic Kidney Disease , 2015, Current Diabetes Reports.
[57] A. Schmidt. 22016 ATVB Plenary Lecture: Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis and Treatment of Cardiometabolic Disorders: Spotlight on the Macrophage. , 2017, Arteriosclerosis, thrombosis, and vascular biology.
[58] R. McPherson,et al. Partitioning the heritability of coronary artery disease highlights the importance of immune-mediated processes and epigenetic sites associated with transcriptional activity , 2017, Cardiovascular research.
[59] Michael E. Miller,et al. Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial , 2014, Diabetes Care.
[60] M. Anselmino,et al. Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery , 2017, Scientific Reports.
[61] K. Channon,et al. Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus: Role of NAD(P)H Oxidase and Endothelial Nitric Oxide Synthase , 2002, Circulation.
[62] M. Saad,et al. Insulin resistance in essential hypertension. , 1990, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[63] P. Libby,et al. Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists , 2007 .
[64] Hong Nie,et al. Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2H-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress , 2017, The Journal of Pharmacology and Experimental Therapeutics.
[65] R. Taylor,et al. Restoring normoglycaemia by use of a very low calorie diet in long‐ and short‐duration Type 2 diabetes , 2015, Diabetic medicine : a journal of the British Diabetic Association.
[66] Liam G. Fearnley,et al. An interaction map of circulating metabolites, immune gene networks, and their genetic regulation , 2016, Genome Biology.
[67] K. Otsu,et al. Inflammation and metabolic cardiomyopathy. , 2017, Cardiovascular research.
[68] A. Schmidt. 22016 ATVB Plenary Lecture: Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis and Treatment of Cardiometabolic Disorders: Spotlight on the Macrophage. , 2017, Arteriosclerosis, thrombosis, and vascular biology.
[69] D. Hardie,et al. The mechanisms of action of metformin , 2017, Diabetologia.
[70] Rong Li,et al. Metformin improves obesity-associated inflammation by altering macrophages polarization , 2017, Molecular and Cellular Endocrinology.
[71] Nathan Congdon,et al. The Prevalence of Diabetic Retinopathy in the United States , 2002 .
[72] G. Hotamışlıgil. Inflammation, metaflammation and immunometabolic disorders , 2017, Nature.
[73] L. Moran,et al. Treatment with high dose salicylates improves cardiometabolic parameters: Meta-analysis of randomized controlled trials. , 2017, Metabolism: clinical and experimental.
[74] M. Banerjee,et al. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. , 2012, Clinica chimica acta; international journal of clinical chemistry.
[75] K. Ward,et al. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction , 2017, Cardiovascular Diabetology.
[76] Ralph A. DeFronzo,et al. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.
[77] H. Parving,et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial , 2008, The Lancet.
[78] R. Touyz,et al. Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. , 2014, Journal of the American Society of Nephrology : JASN.
[79] R. DeFronzo,et al. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. , 2015, European heart journal.
[80] P. Formisano,et al. Methylglyoxal-Glyoxalase 1 Balance: The Root of Vascular Damage , 2017, International journal of molecular sciences.
[81] J. Petrie. The cardiovascular safety of incretin-based therapies: a review of the evidence , 2013, Cardiovascular Diabetology.
[82] Krishna A. Adeshara,et al. Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies. , 2016, Current drug targets.
[83] J. Loscalzo,et al. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia , 2002, Vascular medicine.
[84] Lawrence A Leiter,et al. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. , 2017, The Canadian journal of cardiology.
[85] J. Pickering,et al. Cellular Senescence and Vascular Disease: Novel Routes to Better Understanding and Therapy. , 2016, The Canadian journal of cardiology.
[86] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[87] G. Freund,et al. The implication of proinflammatory cytokines in type 2 diabetes. , 2008, Frontiers in bioscience : a journal and virtual library.
[88] R. Gaynor,et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.
[89] R. Singh,et al. Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes. , 2011, Diabetes research and clinical practice.
[90] H R Taylor,et al. Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries , 2013, Diabetic medicine : a journal of the British Diabetic Association.
[91] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[92] D. Harrison,et al. The role of infiltrating immune cells in dysfunctional adipose tissue , 2017, Cardiovascular research.
[93] W. Malaisse. B-cell function in type 2 diabetes , 1990 .
[94] P. Newsholme,et al. Molecular mechanisms of ROS production and oxidative stress in diabetes. , 2016, The Biochemical journal.
[95] R. Touyz,et al. Oxidative Stress, Inflammation, and Vascular Aging in Hypertension , 2017, Hypertension.
[96] E. Barrett,et al. Insulin‐Induced Microvascular Recruitment in Skin and Muscle are Related and Both are Associated with Whole‐Body Glucose Uptake , 2012, Microcirculation.
[97] L. Chatenoud,et al. Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice , 2018, Diabetologia.
[98] A. Scuteri,et al. Endothelial function and arterial stiffness in normotensive normoglycemic first-degree relatives of diabetic patients are independent of the metabolic syndrome. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[99] T. Hansen,et al. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub‐analysis of a randomized, placebo‐controlled, double‐blind, crossover trial , 2017, Diabetes, obesity & metabolism.
[100] J. Beckman,et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.
[101] P. Pozzilli,et al. Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes? , 2013, Diabetes Care.
[103] R. Touyz,et al. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. , 2013, Clinical science.
[104] C. Antoniades. 'Dysfunctional' adipose tissue in cardiovascular disease: a reprogrammable target or an innocent bystander? , 2017, Cardiovascular research.
[105] D. Drucker. The Cardiovascular Biology of Glucagon-like Peptide-1. , 2016, Cell metabolism.
[106] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[107] B. Wells,et al. Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system , 2015, BMJ Open Diabetes Research and Care.
[108] H. Grallert,et al. Effects of Genetic Loci Associated with Central Obesity on Adipocyte Lipolysis , 2016, PloS one.
[109] R. Gaynor,et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. , 1998, Nature.
[110] D. Power,et al. NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy , 2017, Diabetes.
[111] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[112] N. Mishra,et al. Role of MicroRNAs in Type 2 Diabetes and Associated Vascular Complications. , 2017, Biochimie.
[113] K. Lackner,et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats , 2017, Redox biology.
[114] J. Whitehead,et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress , 2014, Nature Medicine.
[115] R. Touyz,et al. Vascular biology of ageing—Implications in hypertension , 2015, Journal of Molecular and Cellular Cardiology.
[116] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[117] F. Rubino,et al. Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial , 2015, The Lancet.
[118] A. Donker,et al. Effects of short‐term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo‐controlled trial , 2005, Journal of internal medicine.
[119] E. Schiffrin,et al. Oxidative Stress, Nox Isoforms and Complications of Diabetes—Potential Targets for Novel Therapies , 2012, Journal of Cardiovascular Translational Research.
[120] C. Peterson,et al. Pioglitazone Treatment Reduces Adipose Tissue Inflammation through Reduction of Mast Cell and Macrophage Number and by Improving Vascularity , 2014, PloS one.
[121] A. Ferro,et al. The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials. , 2016, Cardiovascular research.
[122] F. Porzsolt,et al. Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.
[123] A. Donker,et al. Long‐term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial , 2014, Journal of internal medicine.
[124] P. Wilson,et al. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. , 1988, JAMA.